|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.33 USD | -3.21% |
|
+32.54% | +323.54% |
| 06-14 | Wells Fargo Raises Price Target on Avidity Biosciences to $75 From $50, Maintains Overweight Rating | MT |
| 06-14 | Avidity Biosciences Prices $400.9 Million Offering of Shares | MT |
In January 2020, Avidity Biosciences, Inc. closed the transaction. The company has amended the terms and issued 18,452,757 series C convertible preferred shares for gross proceeds of $78,999,943.2684 in the transaction. The company has issued 537,232 series C convertible preferred shares for gross proceeds of $2,299,997.6384 in its second tranche.
The company has paid $100,000 as issue expenses in second tranche.
| 1st Jan change | Capi. | |
|---|---|---|
| +323.54% | 4.2B | |
| +2.31% | 92.1B | |
| -2.63% | 37.92B | |
| -13.57% | 32.97B | |
| +75.60% | 27.92B | |
| -12.73% | 16.14B | |
| -2.15% | 14.1B | |
| -11.93% | 11.66B | |
| +177.66% | 10.29B | |
| -50.94% | 9.99B |
AVIDITY BIOSCIENCES, INC. 
